908 related articles for article (PubMed ID: 15231022)
1. RANKL coordinates cell cycle withdrawal and differentiation in osteoclasts through the cyclin-dependent kinase inhibitors p27KIP1 and p21CIP1.
Sankar U; Patel K; Rosol TJ; Ostrowski MC
J Bone Miner Res; 2004 Aug; 19(8):1339-48. PubMed ID: 15231022
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction.
Kobayashi K; Takahashi N; Jimi E; Udagawa N; Takami M; Kotake S; Nakagawa N; Kinosaki M; Yamaguchi K; Shima N; Yasuda H; Morinaga T; Higashio K; Martin TJ; Suda T
J Exp Med; 2000 Jan; 191(2):275-86. PubMed ID: 10637272
[TBL] [Abstract][Full Text] [Related]
3. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation.
Lee SE; Woo KM; Kim SY; Kim HM; Kwack K; Lee ZH; Kim HH
Bone; 2002 Jan; 30(1):71-7. PubMed ID: 11792567
[TBL] [Abstract][Full Text] [Related]
4. Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21(WAF1/CIP1) and p27(KIP1).
Okahashi N; Murase Y; Koseki T; Sato T; Yamato K; Nishihara T
J Cell Biochem; 2001; 80(3):339-45. PubMed ID: 11135363
[TBL] [Abstract][Full Text] [Related]
5. In vitro differentiation of CD14 cells from osteopetrotic subjects: contrasting phenotypes with TCIRG1, CLCN7, and attachment defects.
Blair HC; Borysenko CW; Villa A; Schlesinger PH; Kalla SE; Yaroslavskiy BB; Garćia-Palacios V; Oakley JI; Orchard PJ
J Bone Miner Res; 2004 Aug; 19(8):1329-38. PubMed ID: 15231021
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population.
Nagata N; Kitaura H; Yoshida N; Nakayama K
Bone; 2003 Oct; 33(4):721-32. PubMed ID: 14555278
[TBL] [Abstract][Full Text] [Related]
7. Osteoclast differentiation is impaired in the absence of inhibitor of kappa B kinase alpha.
Chaisson ML; Branstetter DG; Derry JM; Armstrong AP; Tometsko ME; Takeda K; Akira S; Dougall WC
J Biol Chem; 2004 Dec; 279(52):54841-8. PubMed ID: 15485831
[TBL] [Abstract][Full Text] [Related]
8. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
9. Limited rescue of osteoclast-poor osteopetrosis after successful engraftment by cord blood from an unrelated donor.
Nicholls BM; Bredius RG; Hamdy NA; Gerritsen EJ; Lankester AC; Hogendoorn PC; Nesbitt SA; Horton MA; Flanagan AM
J Bone Miner Res; 2005 Dec; 20(12):2264-70. PubMed ID: 16294279
[TBL] [Abstract][Full Text] [Related]
10. Osteoclast differentiation by RANKL requires NF-kappaB-mediated downregulation of cyclin-dependent kinase 6 (Cdk6).
Ogasawara T; Katagiri M; Yamamoto A; Hoshi K; Takato T; Nakamura K; Tanaka S; Okayama H; Kawaguchi H
J Bone Miner Res; 2004 Jul; 19(7):1128-36. PubMed ID: 15176996
[TBL] [Abstract][Full Text] [Related]
11. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
[TBL] [Abstract][Full Text] [Related]
12. Interleukin (IL)-12 mediates the anti-osteoclastogenic activity of CpG-oligodeoxynucleotides.
Amcheslavsky A; Bar-Shavit Z
J Cell Physiol; 2006 Apr; 207(1):244-50. PubMed ID: 16402377
[TBL] [Abstract][Full Text] [Related]
13. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells.
Yang CR; Wang JH; Hsieh SL; Wang SM; Hsu TL; Lin WW
Cell Death Differ; 2004 Jul; 11 Suppl 1():S97-107. PubMed ID: 15002040
[TBL] [Abstract][Full Text] [Related]
14. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
15. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
Chu K; Snyder R; Econs MJ
J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
[TBL] [Abstract][Full Text] [Related]
16. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
17. Direct stimulation of osteoclastogenesis by MIP-1alpha: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL.
Watanabe T; Kukita T; Kukita A; Wada N; Toh K; Nagata K; Nomiyama H; Iijima T
J Endocrinol; 2004 Jan; 180(1):193-201. PubMed ID: 14709158
[TBL] [Abstract][Full Text] [Related]
18. Effects of the phytoestrogen coumestrol on RANK-ligand-induced differentiation of osteoclasts.
Kanno S; Hirano S; Kayama F
Toxicology; 2004 Oct; 203(1-3):211-20. PubMed ID: 15363596
[TBL] [Abstract][Full Text] [Related]
19. TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors.
Zauli G; Rimondi E; Stea S; Baruffaldi F; Stebel M; Zerbinati C; Corallini F; Secchiero P
J Cell Physiol; 2008 Jan; 214(1):117-25. PubMed ID: 17620297
[TBL] [Abstract][Full Text] [Related]
20. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
